The short version is that GLP-1s can produce meaningful weight loss and better metabolic markers, but only for those who tolerate the medication, stay engaged for months and pair it with consistent lifestyle habits
While the potential cost of authorizing Medicare coverage of anti-obesity drugs has presented a barrier to enacting legislation to lift the prohibition, covering these drugs under Medicare for authorized uses has already catapulted these drugs to rank among the top-selling drugs covered by Part D, Medicares outpatient drug benefit program
Products in this category are sometimes marketed using terms like "GLP-1 patch," which reflects consumer search behavior rather than verified biological function
Second, GLP-1 drugs shrink appetite dramatically, which often means people eat far less food overall, and far less fiber specifically
Why wasnt this addressesd in the article